HC Wainwright Issues Positive Outlook for SPRB Earnings

Spruce Biosciences, Inc. (NASDAQ:SPRB) – Analysts at HC Wainwright boosted their Q1 2026 earnings per share (EPS) estimates for shares of Spruce Biosciences in a research report issued on Tuesday, March 10th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($8.92) per share for the quarter, up from their previous estimate of ($10.46). HC Wainwright has a “Buy” rating and a $200.00 price objective on the stock. The consensus estimate for Spruce Biosciences’ current full-year earnings is ($1.00) per share. HC Wainwright also issued estimates for Spruce Biosciences’ Q2 2026 earnings at ($8.20) EPS, Q3 2026 earnings at ($8.08) EPS, Q4 2026 earnings at ($7.56) EPS, FY2026 earnings at ($32.66) EPS and FY2027 earnings at ($14.12) EPS.

SPRB has been the subject of several other research reports. Citizens Jmp reduced their target price on shares of Spruce Biosciences from $180.00 to $170.00 and set a “market outperform” rating for the company in a report on Tuesday. Oppenheimer initiated coverage on Spruce Biosciences in a research note on Tuesday, December 23rd. They set an “outperform” rating and a $283.00 price objective for the company. Wall Street Zen downgraded Spruce Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, December 27th. Leerink Partners raised Spruce Biosciences from a “market perform” rating to an “outperform” rating and set a $160.00 target price on the stock in a report on Wednesday, December 3rd. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Spruce Biosciences in a research report on Monday, December 29th. Four research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $170.10.

Spruce Biosciences Trading Up 2.2%

SPRB opened at $64.18 on Thursday. Spruce Biosciences has a 12-month low of $4.28 and a 12-month high of $240.00. The firm has a 50 day moving average of $71.29 and a two-hundred day moving average of $75.85. The firm has a market capitalization of $68.67 million, a PE ratio of -1.24 and a beta of 3.62.

Spruce Biosciences (NASDAQ:SPRB) last announced its quarterly earnings data on Thursday, March 12th. The company reported ($9.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($9.16) by ($0.42).

Institutional Trading of Spruce Biosciences

Institutional investors and hedge funds have recently made changes to their positions in the business. SkyView Investment Advisors LLC acquired a new position in shares of Spruce Biosciences during the 4th quarter worth approximately $261,000. State Street Corp acquired a new stake in shares of Spruce Biosciences in the fourth quarter valued at about $558,000. Superstring Capital Management LP acquired a new stake in shares of Spruce Biosciences in the fourth quarter valued at about $1,057,000. Geode Capital Management LLC purchased a new stake in shares of Spruce Biosciences during the fourth quarter worth about $1,109,000. Finally, Caligan Partners LP acquired a new stake in Spruce Biosciences in the 4th quarter worth about $1,787,000. 91.71% of the stock is currently owned by hedge funds and other institutional investors.

About Spruce Biosciences

Spruce Biosciences, Inc is a clinical-stage biopharmaceutical company dedicated to developing therapies for rare endocrine and dermatological disorders. Headquartered in San Diego, California, Spruce focuses on conditions with significant unmet medical needs, employing a precision medicine approach to identify and advance treatment candidates through late-stage clinical trials.

The company’s lead asset, tildacerfont, is an oral corticotropin-releasing factor type 1 (CRF1) receptor antagonist being evaluated for the treatment of congenital adrenal hyperplasia (CAH), a genetic disorder characterized by insufficient cortisol production and excess androgen levels.